Rheumatology treats musculoskeletal and autoimmune diseases, including arthritis, lupus, gout, and vasculitis.
Send us all your questions or requests, and our expert team will assist you.
Diagnosing Systemic Lupus Erythematosus is a complex clinical puzzle because no single test can definitively confirm the disease. Instead, the diagnosis is based on a combination of clinical observations and laboratory evidence. To bring order to this complexity, specialized organizations like the American College of Rheumatology and the Systemic Lupus International Collaborating Clinics have established classification criteria. These criteria are designed to ensure specificity and sensitivity in research and clinical practice.
A definitive diagnosis generally requires a patient to meet a specific number of clinical and immunologic criteria, typically including at least one clinical symptom (such as malar rash, arthritis, or nephritis) and one immunologic marker (such as specific autoantibodies). This multiparametric approach is necessary because many lupus symptoms overlap with those of other connective tissue diseases. The evaluation process is dynamic; symptoms may not all present simultaneously, requiring physicians to monitor patients over time to observe the accumulation of criteria that point towards lupus.
The cornerstone of lupus laboratory evaluation is the Antinuclear Antibody test. This test screens for antibodies that target the cell nucleus. It is susceptible, meaning that nearly all patients with lupus will test positive. However, it is not specific; a positive ANA can occur in other autoimmune diseases, infections, and even in healthy individuals. Therefore, a positive ANA serves only as a gateway to more specific testing.
If the ANA is positive, a cascade of further tests is initiated to identify specific autoantibodies. Anti-double-stranded DNA (anti-dsDNA) is specific for lupus, and its levels often correlate with disease activity, particularly nephritis. Anti-Smith (anti-Sm) antibodies are also distinct from lupus but are seen in a smaller proportion of patients. Anti-Ro and Anti-La antibodies are associated with cutaneous lupus and increased risk of neonatal lupus. The presence of these specific antibodies helps to confirm the diagnosis and can provide prognostic information regarding the likely course of the disease and organ involvement.
The evaluation of the complement system provides critical insight into the disease’s activity. Complement proteins, specifically C3 and C4, are consumed during the formation of immune complexes. Therefore, low levels of C3 and C4 in the blood often indicate active disease and ongoing immune complex deposition in tissues, particularly in the kidneys. Monitoring these levels helps clinicians assess whether the disease is flaring or responding to treatment.
Non-specific inflammatory markers such as the Erythrocyte Sedimentation Rate and C-Reactive Protein are also routinely measured. While an elevated sedimentation rate is common in active lupus, C-reactive protein levels may remain normal or only slightly elevated unless there is active serositis or a concurrent infection. This discrepancy can sometimes help distinguish a lupus flare from a bacterial infection, which typically causes a massive spike in C-reactive protein.
Once a diagnosis is suspected or confirmed, a comprehensive evaluation of organ systems is mandatory to determine the extent of the disease. Renal evaluation is paramount. This involves urinalysis to check for protein, blood, and cellular casts, as well as blood tests for creatinine to estimate kidney function. If lupus nephritis is suspected, a renal biopsy is the gold standard. This invasive procedure involves taking a small sample of kidney tissue to examine under a microscope. It allows the pathologist to classify the nephritis into one of six classes, guiding the intensity of immunosuppressive therapy required to prevent scarring and preserve renal function.
Cardiac and pulmonary evaluations may include echocardiograms to assess for pericardial effusion or valve abnormalities, and chest X-rays or CT scans to look for pleural effusions or interstitial lung disease. In patients with neuropsychiatric symptoms, MRI of the brain and cerebrospinal fluid analysis may be necessary to rule out infection and assess for inflammatory changes associated with lupus.
In the context of advanced cellular medicine, lupus evaluation is moving towards identifying biomarkers that predict tissue damage and regenerative potential. Research is focused on urinary biomarkers that can detect renal flares earlier than standard proteinuria measurements. Cytokine profiling, measuring levels of specific interferons and interleukins, helps in sub-typing patients who might respond better to specific biologic therapies.
Furthermore, evaluating the health of the patient’s progenitor cells is becoming a relevant research tool. Assessing the function of circulating endothelial progenitor cells, which repair blood vessels, can provide information about cardiovascular risk. In the future, evaluation might include assessing the viability of a patient’s own mesenchymal stem cells to determine if they are suitable candidates for autologous regenerative therapies, or if allogenic (donor) cells would be more effective in restoring immune tolerance.
While not yet routine in all clinical settings, genetic screening can identify monogenic forms of lupus, particularly in pediatric cases involving complement deficiencies. Understanding the genetic background can explain disease severity. Epigenetic evaluation, which examines how genes are turned on or off by environmental factors, provides insight into the mechanisms of drug-induced lupus and the role of environmental triggers. This level of evaluation aligns with the goals of precision medicine, tailoring the understanding of the disease to the individual’s unique molecular landscape.
Send us all your questions or requests, and our expert team will assist you.
The ANA test is a screening tool that detects antibodies against cell nuclei. While most people with lupus have a positive ANA, so do many people with other autoimmune diseases, infections, or even healthy individuals. Therefore, a positive ANA indicates the need for further, more specific testing but, by itself, does not confirm a diagnosis of lupus.
A kidney biopsy allows doctors to examine the actual tissue to see the extent and type of inflammation and damage. Lupus nephritis is classified into 6 classes (I-VI), and each class requires a different treatment approach. The biopsy also helps distinguish between active inflammation, which can be treated, and permanent scarring, which cannot.
Complement proteins are used up when the immune system forms complexes to attack tissue. Therefore, when lupus is highly active and causing damage, the levels of complement proteins C3 and C4 in the blood typically drop. Rising levels usually indicate that the treatment is working and the disease activity is subsiding.
Anti-double-stranded DNA antibodies are particular to lupus and are rarely found in other conditions. Significantly, the levels of these antibodies often fluctuate with disease activity, rising during flares and falling during remission. They are particularly associated with the risk of developing kidney disease (lupus nephritis).
Urine tests are the earliest warning system for lupus nephritis. Kidney damage can occur without any pain or noticeable symptoms. Regular urine tests detect microscopic amounts of blood or protein, alerting the physician to kidney inflammation long before it causes kidney failure or physical swelling.
Your Comparison List (you must select at least 2 packages)
